Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Raw Materials (2016 - 2019)

Aptevo Therapeutics (APVO) has disclosed Raw Materials for 5 consecutive years, with $491000.0 as the latest value for Q4 2019.

  • Quarterly Raw Materials rose 153.09% to $491000.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $491000.0 through Dec 2019, up 153.09% year-over-year, with the annual reading at $491000.0 for FY2019, 153.09% up from the prior year.
  • Raw Materials hit $491000.0 in Q4 2019 for Aptevo Therapeutics, down from $640000.0 in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $7.6 million in Q2 2016 to a low of $43000.0 in Q3 2018.
  • Historically, Raw Materials has averaged $1.4 million across 5 years, with a median of $244500.0 in 2017.
  • Biggest five-year swings in Raw Materials: tumbled 96.74% in 2017 and later surged 1388.37% in 2019.
  • Year by year, Raw Materials stood at $6.5 million in 2015, then plummeted by 96.01% to $260000.0 in 2016, then plummeted by 78.46% to $56000.0 in 2017, then soared by 246.43% to $194000.0 in 2018, then surged by 153.09% to $491000.0 in 2019.
  • Business Quant data shows Raw Materials for APVO at $491000.0 in Q4 2019, $640000.0 in Q3 2019, and $612000.0 in Q2 2019.